NEW YORK (360Dx) – In an industry responding to laboratory consolidation and health systems looking to purchase systems that can handle larger volumes and broader test menus, Abbott believes that molecular labs can benefit from moving testing currently done by several instruments onto a single platform.
Its solution to facilitate this change is the Alinity m real-time PCR-based molecular platform.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
